The structural reasons behind the world’s most common antibiotic shortage, traced from API manufacturing in India to dispensary shelves in Australia.
Formulary flexibility, safety stock strategies and the rise of real-time monitoring across five major hospital networks.
How different regulatory frameworks create asymmetric shortage risk and what it means for cross-border supply strategies.
Quarterly analysis of shortage trends across the markets we index, covering severity distribution, resolution timelines, and the most-affected therapeutic classes.
Why aminopenicillins are the most at-risk drug class globally, and what the data says about recovery timelines.
Tracking upstream manufacturing risk across Indian and Chinese API facilities and their downstream impact on finished-dose availability.
198 new shortage records added across Southeast Asia.
Australian shortage data now among the fastest-updating sources globally.
Nordic coverage now complete with NoMA shortage declarations tracked and normalised.
Shortage alerts, new data releases and analysis — one concise email per week.